Prof. Mathias Mäurer discusses in this video about the new form of therapy and the current status of results on CAR-T cell therapy for MS.
Please consider using the automated translation of YouTube. You can activate this function by clicking on the settings symbol and choosing subtitles.
The CAR-T cell therapy comes from oncology, where it is used primarily successfully in B-cell lymphoma. Now studies are also underway for Multiple Sclerosis. The interesting thing about it: It could particularly help to treat progressive MS courses.
Phase-2 studies on CAR-T cells for MS in Germany
Phase-2 studies are currently being conducted in Germany. Participants are still being sought in some cases. However, Prof. Mathias Mäurer expressly points out that patients should use currently available therapies instead of waiting to participate in such a study.
It is not yet certain whether CAR-T cell therapy will really help with Multiple Sclerosis. The results of phase-3 studies must be awaited for this. Results from phase-2 studies are not expected for another 6 to 12 months. Only then can it be decided whether approval studies will be conducted at all. So, in the best-case scenario, it will be a few more years before CAR-T cell therapy could be approved for Multiple Sclerosis.